Around 70% of children who survive a brain tumour develop at least one form of endocrine dysfunction, suggests a long-term study of patients attending a hospital in Portugal.
Collagenopathies could account for around one in 10 cases of familial short stature even when there are no obvious signs of dysplasia, say researchers.
A study of children with Noonan syndrome treated in clinical practice shows a good response to growth hormone treatment, with the majority achieving a height within population norms.
A single measurement of plasma levels of a fragment of type X collagen may give an instant picture of how fast a child is growing, say researchers.
Rare copy number variants have been identified in a study of children who have growth hormone insensitivity or insulin-like growth factor-1 insensitivity, shedding light on the genetic basis of their conditions.
Dr Cheri Deal discusses the use of growth hormone in children with Prader-Willi syndrome, the importance of multidisciplinary care and the future of treatment for this genetic condition.
Following the publication of the long-term mortality findings of the SAGhE consortium, we discuss the safety profile of growth hormone with consortium member Stefano Cianfarani.
Children who receive total body irradiation or craniospinal radiation for cancer may have a reduced response to growth hormone therapy if they later require it, say researchers.
Less than 10% of brain magnetic resonance imaging scans in children with isolated growth hormone deficiency reveal a pathological cause, say researchers.
Receiving treatment with recombinant human growth hormone in childhood is unlikely to be associated with an increased risk for mortality in the long term, show the results of the full SAGhE cohort.